| |
| |
Download and print a copy of the newsletter.
You will need Adobe® Acrobat® Reader to view this PDF.
|
| |
| Download (PDF,485K) > |
| |
A newsletter that reviews and
summarizes key literature about
identification, risks, and
management of transfusional
iron overload.
This first issue focuses on iron
overload in myelodysplastic
syndromes (MDS), which comprise a heterogeneous
group of myeloid clonal disorders characterized by
ineffective hematopoiesis. Subsequent issues will
focus on other topics surrounding transfusional iron
overload and its health consequences.
|
| |
|
| |
| |
- Introduction
- Management of Iron Overload in the Myelodysplastic Syndromes
- Evaluation of Iron Levels to Avoid the Clinical Sequelae of IronOverload
Taher A, Nathan D, Porter J. Semin Hematol. 2007;44:S2–S6.
- Red Blood Cell Transfusions and Iron Overload in the Treatment of Patients With Myelodysplastic Syndromes
Jabbour E, Kantarjian HM, Koller C, Taher A. Cancer. 2008; 112:1089–1095.
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
Malcovati L, Della Porta MG, Pascutto C, et al. J Clin Oncol.
2005;23:7594–7603.
- Current Treatment Options for MDS
Garcia-Manero G, Yang AS, Jagasia M. Clin Adv Hematol. Oncol. 2007;5:1–9.
- Retrospective Nationwide Survey of Japanese Patients with Transfusion-Dependent MDS and Aplastic Anemia Highlights the Negative Impact of Iron Overload on Morbidity/Mortality
Takatoku M, Uchiyama T, Okamoto S, et al. Eur J Haematol.
2007;7:487–494.
|
| |
| Download (PDF,485K) > |
| |
| |
|
| |
